Altun and colleagues demonstrated that atorvastatin (40 mg/day) treatment in patients with acute coronary syndrome improved the flow-mediated vasodilation, which was accompanied with a decrease in the adhesion molecules E-selectin and sICAM-1 and the inflammatory marker C-reactive protein (CRP) [81]. This evidence concerns the gene CRP and acute coronary syndrome.